arsenic has been researched along with Leukemia, Myeloid, Acute, M4 in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowen, D; Burnett, AK; Cahalin, P; Craig, J; Hills, RK; Hunter, A; Kell, J; McMullin, MF; Milligan, D; Russell, N; Wheatley, K; Yin, J | 1 |
| Andreeff, M; Cheng, X; Freireich, EJ; Gao, MZ; Golemovic, M; Kantarjian, HM; Quintás-Cardama, A; Verstovsek, S; Zingaro, R | 1 |
| Farhat, M; Venugopal, P | 1 |
| Zhang, Z | 1 |
2 review(s) available for arsenic and Leukemia, Myeloid, Acute, M4
| Article | Year |
|---|---|
Long-term remission of extramedullary relapse from acute promyelocytic leukemia after treatment with arsenic trioxide, intrathecal chemotherapy, and brain irradiation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cranial Irradiation; Daunorubicin; Ear Neoplasms; Humans; Injections, Spinal; Leukemia, Myelomonocytic, Acute; Male; Oxides; Radiography; Remission Induction; Sarcoma, Myeloid; Tretinoin | 2007 |
[Progresses in the study of hematology in China, 1997].
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Oxides; Thrombophlebitis | 1997 |
1 trial(s) available for arsenic and Leukemia, Myeloid, Acute, M4
| Article | Year |
|---|---|
The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Chemical and Drug Induced Liver Injury; Comorbidity; Cytarabine; Disease-Free Survival; Early Termination of Clinical Trials; Female; Gastrointestinal Diseases; Heart Diseases; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Middle Aged; Oxides; Remission Induction; Treatment Outcome | 2011 |
1 other study(ies) available for arsenic and Leukemia, Myeloid, Acute, M4
| Article | Year |
|---|---|
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Caspase 9; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Female; HL-60 Cells; Humans; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Mice; Oncogene Proteins, Fusion; Oxides; Oxygen | 2012 |